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Novelty statement:  5 
 This paper describes baseline data from the first prospective multicentre study using the 6 
proteomics classifier CKD273 for risk stratification in individuals with normoalbuminuria 7 
and type 2 diabetes. 8 
 Previously, post-hoc analyses have shown that CKD273 identifies individuals at high risk of 9 
developing DKD. This study demonstrates that the associations between the CKD273 10 
proteomic pattern and traditional risk factors for DKD are weak with small numerical 11 
differences for the traditional risk factors. CKD273 may provide additional information on 12 
risk for DKD.  13 
 Interesting differences among sites across Europe in prevalence of CKD273 pattern cannot 14 
be explained by traditional risk factors for DKD. 15 
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Abstract 1 
Aims 2 
To compare clinical baseline data in individuals with type 2 diabetes and normoalbuminuria, at 3 
high- or low-risk for diabetic kidney disease (DKD) based on the urinary proteomics classifier 4 
CKD273. 5 
 6 
Methods 7 
Prospective, randomized, double-blind, placebo-controlled international multicentre clinical trial 8 
and observational study in participants with type 2 diabetes and normoalbuminuria, stratified into 9 
high- or low-risk groups based on CKD273 score. Here we present clinical baseline data in the 10 
whole cohort and by risk groups. By univariate and logistic regression the associations between 11 
CKD273 and traditional risk factors for DKD are evaluated. 12 
 13 
Results 14 
From 15 centres 1777 participants were included, with 12.3% having a high-risk proteomic pattern. 15 
Participants in the high-risk group (n=218), were more likely men, were older, had longer diabetes 16 
duration, lower eGFR and higher urine albumin-to-creatinine ratio (UACR) than low-risk 17 
participants (n=1559, p<0.02). Numerical differences were small and univariate regression analyses 18 
of CKD273 vs. each baseline variable demonstrated weak associations (R2 < 0.04). In a logistic 19 
regression model including clinical variables known to be associated with DKD, eGFR, gender, 20 
logUACR and use of RAS-blocking agents remained significant determinants of CKD273 high-risk 21 
group, AUC 0.72 (95% CI: 0.68-0.75, p<0.01). 22 
 23 
Conclusions 24 
In this population of individuals with type 2 diabetes and normoalbuminuria, traditional DKD risk 25 
factors differed slightly between participants at high- and low-risk for DKD, based on CKD273. 26 
These data suggest that CKD273 may provide additional prognostic information over and above the 27 
parameters routinely available in the clinic. Testing the added value will be subject to our ongoing 28 
study. 29 
 30 
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Introduction 1 
Diabetic kidney disease (DKD) is a frequent and costly complication of diabetes. Despite 2 
established therapies, this complication is associated with substantial cardiovascular morbidity and 3 
mortality and is the leading cause of end stage renal disease (ESRD) in the Western world (1). DKD 4 
is in clinical practice diagnosed by albuminuria and/or decrease in estimated glomerular filtration 5 
rate (eGFR). Although treatment with RAS blocking agents in persons with micro- and 6 
macroalbuminuria and control of cardiovascular risk factors has improved outcome (2, 3), the 7 
prognosis is still poor. Use of the aldosterone receptor antagonist spironolactone on top of RAS 8 
inhibition has previously been shown to effectively further reduce albuminuria (4-6). However, 9 
long-term as well as larger studies with hard endpoints such as ESRD are missing.  10 
Previous studies with RAS inhibition for prevention of microalbuminuria have shown conflicting 11 
results (7-10). To our knowledge, no studies using spironolactone as prevention of 12 
microalbuminuria have been conducted. Currently, there are no recommendations for prevention of 13 
development of microalbuminuria in diabetes, except for optimal control of metabolic and 14 
cardiovascular risk factors. 15 
Biomarkers based on pathways leading to development and progression of DKD, have the potential 16 
to identify subjects at high risk of progression to renal complications. This would allow for early 17 
intervention only in a population at increased risk, thus allowing for better allocation of treatment. 18 
In 2010, Good et al. identified CKD273 a urinary biomarker pattern including 273 peptides 19 
significantly associated with overt kidney disease (11). This proteomics based pattern detected 20 
initiation and progression of DKD earlier than the currently used indicators (12-15), well preceding 21 
change in albuminuria class. However, all previous data on CKD273 derive from analysis of stored 22 
samples and post hoc analyses of previously conducted studies. 23 
In the ongoing “Proteomic prediction and renin angiotensin aldosterone system inhibition 24 
prevention of early diabetic nephropathy in type 2 diabetic participants with normoalbuminuria” 25 
(PRIORITY) study we address the following questions: first, to validate that the proteomic 26 
classifier CKD273 can predict development of microalbuminuria in persons with type 2 diabetes 27 
and normoalbuminuria prospectively; second to determine whether intervention with a 28 
mineralocorticoid receptor antagonist (spironolactone) on top of standard therapy can reduce the 29 
risk of developing microalbuminuria in individuals with a high-risk CKD273 score.  30 
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For the present manuscript, the primary objective is to evaluate clinical data in individuals stratified 1 
according to CKD273 risk pattern in this first prospectively collected study population applying 2 
CKD273-based risk stratification. Secondly, to evaluate associations between CKD273 and 3 
traditional risk factors for DKD and compare high- and low-risk participants across centres to 4 
explore potential heterogeneity at study baseline. 5 
 6 
Materials and methods 7 
Study Design 8 
PRIORITY is an investigator-initiated, prospective, randomized, double-blind, placebo-controlled 9 
international multicentre clinical trial and observational study in persons with type 2 diabetes and 10 
normoalbuminuria funded by the European Commission’s Seventh Framework programme. The 11 
detailed rationale, study design and methods for PRIORITY have been published elsewhere (16). 12 
Briefly, persons aged 18-75 with type 2 diabetes, preserved kidney function and normoalbuminuria, 13 
were included. The participants were required to fulfil the following inclusion criteria: 14 
normoalbuminuria (urine albumin-to-creatinine ratio (UACR) <30 mg/g) in at least two out of three 15 
consecutive morning void urine samples and eGFR >45 ml min-1 1.73 m-2 at screening. Participants 16 
were stratified into high- or low-risk groups based on their CKD273 score, of a single urine sample 17 
collected at screening. High-risk was defined as CKD273-classifier score >0.154, low-risk as 18 
≤0.154 as previously described (15, 16). Participants in the high-risk group were stratified based on 19 
use of RAS blocking agents and randomly assigned to either spironolactone 25 mg once daily or 20 
placebo, on top of standard care. The participants in the low-risk group are followed on standard 21 
care. The study period has been extended from 3 to 4.5 years in a protocol amendment, primarily 22 
due to delayed recruitment. Based on expected higher progression rates to microalbuminuria due to 23 
extension in treatment/observation time as well as new knowledge on treatment effect (10), 24 
estimated sample size was revisited with preserved statistical power. All participants are planned for 25 
a final visit in autumn 2018. 26 
The protocol and amendments have been approved by the respective national competent authorities 27 
using in part the Voluntary Harmonisation Procedure. A positive opinion by the responsible ethical 28 
committees was obtained for each participating clinical site. All participants provided written 29 
  
 
 
7 
informed consent at screening and again after the protocol amendment. The study is conducted in 1 
accordance with the International Conference on Harmonisation – Good clinical practice (ICH-2 
GCP), Declaration of Helsinki. An external independent data monitoring committee (DMC) will 3 
monitor safety throughout the study. EU Clinical Trials Register (EudraCT: 2012-000452-34) and 4 
http://www.clinicaltrial.gov (NCT02040441). 5 
 6 
Biochemical and other analyses 7 
At baseline biochemical samples for measurement of creatinine, HbA1c, potassium, sodium, and 8 
lipids were analysed at the local routine laboratory at each study centre by standardised methods. 9 
eGFR was calculated at the local study centre and centrally by the CKD-EPI equation based on 10 
locally measured creatinine with a standardised method. UACR was measured at the central 11 
laboratory at Steno Diabetes Center Copenhagen using Vitros® 5600 MicroSlide. Samples were 12 
shipped frozen on dry-ice from study centres. Confirmed microalbuminuria was defined as UACR 13 
>30 mg/g in at least two of three first morning voids with 30% increase (geometric mean) in UACR 14 
from ‘run-in-phase’, or >40 mg/g (geometric mean). 15 
Urine proteomics was performed by applying capillary electrophoresis mass spectrometry (CE-MS) 16 
analysis at Mosaiques Diagnostics in Hannover, Germany. In brief, this provides data on >1000 17 
identified proteins or peptides and a predefined renal risk profile based on 273 peptides (CKD273). 18 
The limit of detection for individual peptides is ~ 1 fmol and mass resolution is above 8000, 19 
enabling resolution of monoisotopic mass signals for z ≤ 6. Details on the analysis have previously 20 
been described (16, 17). 21 
 22 
Medical history 23 
Data collections regarding concomitant medication, medical history, smoking status and diabetes 24 
duration were based on local medical records and self-reporting. Hypertension was defined as 25 
medical history of hypertension or concomitant treatment with antihypertensive agents at baseline. 26 
Dyslipidaemia was defined as dyslipidaemia in the medical history or concomitant treatment with 27 
lipid-lowering agents. 28 
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Statistical analysis  1 
Continuous variables are reported as means with standard deviation (SD) for normally distributed 2 
data or median with interquartile range (IQR) for skewed data and are compared between groups 3 
using an unpaired t-test, skewed data are log transformed before comparison between groups. A chi-4 
square test is used for comparison of categorical data. Correlations between baseline variables and 5 
CKD273 score are calculated from a linear regression model and presented as coefficients of 6 
determination (R2) and beta-coefficients. Prediction of CKD273 high-risk group is calculated from 7 
clinical variables in a logistic regression model, including known risk factors for DKD (age, gender, 8 
diabetes duration, systolic blood pressure, eGFR, logUACR, HbA1c, smoking, retinopathy and use 9 
of RAS-blocking agents) and in individual models with logUACR, eGFR and use of RAS-blocking 10 
agents. A receiver operating characteristic (ROC) curve based on the logistic regression model 11 
including known risk factors for DKD is presented. A two-tailed p value of <0.05 is considered 12 
significant. SAS Enterprise Guide version 7.1 (7.100.1.2711) (64-bit) by SAS Institute, Inc., Cary, 13 
NC, USA is used for statistical analysis.  14 
 15 
Results 16 
Enrolment 17 
From March 25th 2014 through end of inclusion on August 31st 2016, a total of 2276 persons from 18 
15 study centres in 10 countries were screened and 1777 participants were included. Of those, 218 19 
participants were in the high-risk group and 1559 participants were in the low-risk group. The 20 
proportion of participants in the high-risk group in the whole study population was 12.3%. The 21 
high-risk rates varied considerably between study centres, ranging from 0% to 27% (Fig. s1). 22 
The screening failure rate was 22% and varied between sites from 6% to 32%. The main reason for 23 
screening failure was presence of microalbuminuria with UACR >30 mg/g (n=133), followed by 24 
HbA1c <48 mmol/mol (6.5%) or >119 mmol/mol (13%) (n=71) and declining to participate (n=58) 25 
as shown in the study flow diagram (Fig. s2). Individuals who were not included in the study had 26 
lower eGFR (p<0.01), higher UACR (p<0.01) and higher potassium (p<0.01) compared to included 27 
individuals (supplementary table s1). Screening failure was therefore most commonly due to 28 
previously unrecognised kidney disease at baseline. 29 
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Baseline characteristics and medication 1 
In total, 1777 participants were included for proteomic assessment. Participants with a high-risk 2 
pattern differed from those with a low-risk pattern: high-risk participants were more likely men, 3 
were older, had longer diabetes duration, lower eGFR and higher UACR (p<0.02), (Table 1). As 4 
mentioned, there was a wide range in the proportion of high-risk participants between sites, but 5 
there were no systematic differences in the traditional risk markers for DKD between centres 6 
(supplementary table s2). With regards to baseline medication, there were also differences between 7 
the high- and low-risk groups (Table 2). Biguanides were more commonly used in the high-risk 8 
group than in the low-risk (p<0.03), ACEi was used more frequently in the high-risk than in the 9 
low-risk group, whereas the use of ARB was lower in the high-risk group (p<0.01). The baseline 10 
concomitant medication divided by study sites is listed in supplementary table s3.    11 
 12 
Medical history 13 
In the entire study population, 13% had a history of background diabetic retinopathy, 3% of 14 
proliferative diabetic retinopathy and 4% of diabetic maculopathy. Laser treatment before baseline 15 
was performed in 4%. At baseline 68% had a history of hypertension, 50% of dyslipidaemia and 16 
12% of ischemic heart disease. No difference was detectable in the history of diabetic retinopathy or 17 
diabetic maculopathy between high- and low-risk groups (p>0.62), however the high-risk group 18 
differed from the low-risk group with more participants having a history of hypertension, 19 
dyslipidaemia and ischemic heart disease (p<0.02), (Table 1). The medical history according to 20 
study sites is shown in supplementary table s4. 21 
 22 
Correlation analysis with established risk factors 23 
Univariate regression analyses of CKD273 vs each baseline variable demonstrated weak 24 
associations with age, diabetes duration, BMI, systolic blood pressure, eGFR, UACR, HDL 25 
cholesterol and triglycerides (p<0.04), (Supplementary table s5). The strongest association was seen 26 
for UACR with R2 of 0.04 and beta of 0.014 (p<0.01) and for eGFR with R2 of 0.03 and beta of -27 
0.005 (p<0.01), suggesting at maximum 4% and 3% of the variation in CKD273 score could be 28 
explained by the variables eGFR and UACR, respectively. Scatterplots of CKD273 and UACR 29 
  
 
 
10 
(Fig. s3) and of CKD273 and eGFR (Fig. s4) are provided in the supplementary material. In a 1 
logistic regression model predicting CKD273 risk stratification to the high-risk group, the area 2 
under the curve (AUC) for eGFR was 0.61 (95% CI: 0.56-0.65) (p<0.01), for logUACR 0.62 (95% 3 
CI: 0.58-0.66) (p<0.01) and for treatment with RAS blocking agents (either ACEi or ARB), the 4 
AUC was 0.64 (95% CI: 0.61-0.66) (p<0.01). In one model including a combination of ten known 5 
risk factors for DKD (gender, diabetes duration, systolic blood pressure, eGFR, logUACR, HbA1c, 6 
smoking, retinopathy and use of RAS-blocking agents) the AUC was 0.72 (95% CI: 0.68-0.75) 7 
(p<0.01) (Fig. 1). In this model gender, eGFR, logUACR and use of RAS-blocking agents remained 8 
significant determinants of CKD273 high-risk group (p<0.01).  9 
 10 
Discussion 11 
In this study, we describe baseline data of the PRIORITY study, prospectively applying the urinary 12 
proteomic based CKD273 kidney disease risk classifier in a large population of individuals with 13 
normoalbuminuria and type 2 diabetes. The ability of CKD273 to add prognostic information 14 
beyond the already available clinical data including eGFR and albuminuria (within the normal 15 
range) has previously been demonstrated in post hoc analyses (13-15, 18). However, the current 16 
ongoing study aims to further verify these findings and to assess feasibility of this approach in the 17 
clinical setting. The aim of the current analysis is to evaluate if high-and low-risk participants based 18 
on CKD273 in this setting, are easily differentiated with the standard clinical data, in order to assess 19 
the potential added value of the classifier. 20 
The study included people with type 2 diabetes and normoalbuminuria, from 15 sites in 10 21 
European countries, on average with relatively long disease duration;  in accordance with this, one 22 
third were being treated with insulin. Overall, participants had reasonably well controlled HbA1c, 23 
lipids and blood pressure, with more use of ARB or ACEi, and normal kidney function with low 24 
albumin excretion and eGFR within the normal range. Small numerical differences were seen in 25 
baseline variables between the high- and low-risk groups. In particular, UACR, which is currently 26 
the best predictor of progression of DKD, was 5 (3–8) mg/g in the low-risk and 7 (4–12) mg/g in 27 
the high-risk group, being statistically, but not clinically, different. Weak correlations were seen 28 
between CKD273 and single baseline variables, with associations explaining <5% of the variability, 29 
suggesting that the proteomics score cannot be fully explained by established risk factors associated 30 
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with DKD. When combining the known traditional risk factors for DKD in one model, association 1 
with high-risk CKD273 score was seen. 2 
Previous studies, all post-hoc analyses of cohorts collected for other purposes without applying a 3 
standardised protocol for collection, storage, transportation or analysis of samples, showed that a 4 
high CKD273 score was associated with progression of renal disease in persons without diabetes 5 
(18-20). Other studies focused on CKD273 as a risk predictor specifically in a population with 6 
diabetes. Zürbig et al. demonstrated that CKD273 predicted progression from normo- to 7 
microalbuminuria 1.5 years before microalbuminuria occurred and that progressors from micro- to 8 
macroalbuminuria could be identified by the classifier 3-5 years before disease progression in 9 
adjusted models (12). At baseline there was a trend towards progressors being older, male, with 10 
higher urine albumin excretion rate, lower eGFR and higher systolic blood pressure compared to 11 
non-progressors. This is similar to what we find in the current PRIORITY study. The findings were 12 
confirmed by Roscioni et al. also in a small case-control study, demonstrating that CKD273 13 
predicted development of albuminuria stage on top of eGFR in a three year period, also when 14 
adjusting for baseline urinary albumin excretion and eGFR (21). In DIRECT-Protect 2, in 15 
participants with type 2 diabetes, 9.8% were identified as high-risk, a lower rate than in the current 16 
study; however a higher cut-point for the CKD273 score was applied (15). The participants had 17 
similar urinary albumin excretion rate and blood pressure at baseline; however, they were younger, 18 
had shorter diabetes duration than the current population and a lower eGFR, which could partly 19 
explain the lower than expected high-risk rate in PRIORITY. Pontillo et al. investigated a large 20 
population primarily diagnosed with diabetes (type 1 and 2) with eGFR decline >5 ml min-1 1.73 m-21 
2 per year as the primary endpoint (14). The authors reported that for baseline ranges of eGFR >70 22 
ml min-1 1.73 m-2, CKD273 had a superior predictive value to urinary albumin excretion for fast 23 
eGFR decline. These findings support the use of CKD273 in the present study population with 24 
relatively high eGFR. 25 
The average prevalence of the high-risk pattern was 12.3%, but ranged from 0 to 27% across 26 
centres. Although standardised procedures including sampling protocols are described for all 27 
centres, slight differences in sample handling and variances in diet and lifestyle between countries 28 
may occur, potentially influencing the urine proteome. The performance of CKD273 across centres 29 
was investigated by Siwy et al. in a case-control study where cases had macroalbuminuria and/or 30 
eGFR <45 ml min-1 1.73 m-2 (22). The performance was similar across sites (AUC value 0.89-1.00). 31 
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The considerable variation in the high-risk CKD273 pattern rate between centres in PRIORITY 1 
might be explained by different recruitment strategies between centres, but when looking at the 2 
variation in baseline characteristics, there is no clear trend in the variables explaining the varying 3 
rates of high-risk individuals.  4 
The study demonstrated that it is feasible to have the results of the proteomics analysis within three 5 
days and therefore to use the test in a clinical setting. The CE-MS analysis is a high-end technology 6 
and the cost is higher than testing for urinary albumin. However, if it proves to predict 7 
microalbuminuria and progression to microalbuminuria can be prevented or delayed with selected 8 
preventive treatment, it may well be cost effective  (23). Moreover, as the technology is developed 9 
further, the expectation is that the cost may be reduced.  10 
We recognise some limitations in our study. Data concerning medical history and other baseline 11 
parameters was partly self-reported, however monitored in accordance with good clinical practice 12 
(GCP). Even though the same in- and exclusion criteria were applied, it may have had an impact 13 
that some centres included participants from primary care, whereas others came from secondary 14 
care settings. However, the differences seen between sites might reflect the nature of a multicentre 15 
setting and thus the study population will provide a more generalizable result. The risk stratification 16 
to high- and low-risk was based on proteomics analysis of one urine sample. We expect that the 17 
variation is limited due to the large number of individual peptides included in the pattern (11), this 18 
issue has however not been extensively studied. Microalbuminuria is an accepted clinically relevant 19 
surrogate for DKD, although not an approved hard endpoint. However, in studies for prevention, it 20 
is nearly impossible to analyse hard endpoints since follow up of participants would last for 21 
decades. The major strengths of the study are the well-described phenotype of a large population 22 
with type 2 diabetes and the prospective design with 4.5 years planned follow-up. 23 
In conclusion, in participants with type 2 diabetes and normoalbuminuria, established risk factors 24 
for DKD differed only slightly, with numerically small differences, between high- and low-risk 25 
participants, grouped according to the CKD273 score. Moreover, a limited correlation was seen 26 
between CKD273 and baseline variables, indicating that the proteomics score may not be explained 27 
by established risk factors and may thereby contribute additional information to the measures 28 
currently available in the clinic. Whether the classifier adds prognostic information compared to the 29 
clinical data will be evaluated with the follow-up of this cohort.  30 
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Table 1 Baseline characteristics of the total study population and by CKD273 subgroup 1 
  Included  
N = 1777 
Low-riska 
N = 1559 
High-riskb 
N = 218 
P-value 
(high vs. low) 
Gender, men 1106 (62) 955 (61) 151 (69) 0.02 
Age, years 63 [57-68] 63 [57-68] 64 [59-68] < 0.01 
Known diabetes duration, years 12 (8) 11 (8) 14 (8) < 0.01 
Body mass index, kg/ m2 30 (5) 30 (5) 31 (5) 0.28 
Systolic blood pressure, mmHg 133 (12) 133 (12) 135 (12) 0.03 
Diastolic blood pressure, mmHg 78 (9) 78 (9) 79 (9) 0.51 
Heart rate, bpm 75 (11) 74 (11) 75 (12) 0.36 
eGFR, ml min-1 1.73 m-2 87 (16) 88 (15) 81 (17) < 0.01 
UACR, mg/ g 5 [3 – 9] 5 [3 – 8]  7 [4 – 12] < 0.01 
Potassium, mmol/ L 4.2 (0.4) 4.2 (0.4) 4.2 (0.4) 0.08 
Sodium, mmol/ L 140 (2) 140 (2) 140 (3) 0.89 
HbA1c, mmol/ mol 57 (12) 57 (12) 59 (13) 0.03 
HbA1c, % 7.4 (1.1) 7.3 (1.1) 7.5 (1.2) 0.03 
Total cholesterol, mmol/ L 4.4 (1.0) 4.4 (1.0) 4.4 (1.1) 0.90 
HDL cholesterol, mmol/ L 1.2 (0.3) 1.2 (0.3) 1.2 (0.3) 0.49 
LDL cholesterol, mmol/ L 2.4 (0.9) 2.4 (0.9) 2.4 (1.0) 0.78 
Triglycerides, mmol/ L 1.6 [1.1-2.3] 1.6 [1.1-2.3] 1.7 [1.2-2.6] 0.10 
Smoking status Current: 243 (14) 
Never: 980 (55) 
Former: 547 (31) 
Unknown: 6 (< 1) 
Current: 223 (14) 
Never: 861 (55) 
Former: 468 (30) 
Unknown: 6 (< 1) 
Current: 20 (9) 
Never: 119 (55) 
Former: 79 (36) 
Unknown: 0 (0)  
0.20 
Diabetic retinopathy No: 1458 (82) 
Simplex: 229 (13) 
Proliferative: 56 (3) 
Unknown: 33 (2) 
No: 1283 (82) 
Simplex: 198 (13) 
Proliferative: 48 (3) 
Unknown: 29 (2) 
No: 175 (80) 
Simplex: 31 (14) 
Proliferative: 8 (4) 
Unknown: 4 (2) 
0.88 
Maculopathy No: 1656 (93) 
Yes: 79 (4) 
Unknown: 41 (2) 
No: 1451 (93) 
Yes: 69 (4) 
Unknown: 38 (2) 
No: 205 (94) 
Yes: 10 (5) 
Unknown: 3 (1) 
0.62 
Laser treatment No: 1674 (94) 
Yes: 76 (4) 
Unknown: 26 (1) 
No: 1470 (94) 
Yes: 66 (4) 
Unknown: 22 (1) 
No: 204 (94) 
Yes: 10 (5) 
Unknown: 4 (2) 
0.86 
Hypertension 1360 (77) 1152 (74) 208 (95) < 0.01 
Dyslipidaemia 1007 (57) 869 (56) 138 (63) < 0.01 
Ischemic heart disease 221 (12) 183 (12) 38 (17) 0.02 
Congestive heart disease 19 (1) 18 (1) 1 (< 1) 0.35 
Other cardiac diseasesc 153 (9) 129 (8) 24 (11) 0.18 
Stroke 75 (4) 63 (4) 12 (6) 0.31 
Peripheral arterial diseased 58 (3) 51 (3) 7 (3) 0.96 
 2 
Mean (SD) or median [IQR] for continuous variables, n (%, rounded) for categorical variables. P value for 3 
chi-square test for categorical variables and unpaired t-test for continuous variables. aCKD273-classifier 4 
below or equal to the cut-point of 0.154. bCKD273-classifier above the cut-point of 0.154. eGFR denotes 5 
estimated glomerular filtration rate, UACR Urine Albumin-to-Creatinine Ratio. cOther cardiac diseases 6 
include arrhythmias, cardiomyopathies, aortic stenosis and valve stenosis. dPeripheral arterial disease include 7 
amputations, aneurisms and carotid stenosis. 8 
 9 
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Table 2 Baseline medication of the whole study population and by CKD273 subgroup 1 
Medication Included 
N = 1777 
Low-riska 
N = 1559 
High-riskb 
N = 218 
P-value 
(high- vs. low-
risk) 
Insulin of any kind 623 (36) 541 (35) 82 (38) 0.37 
Biguanides 1407 (81) 1219 (80) 188 (86) 0.03 
Sulphonylureas 424 (24) 359 (24) 65 (30) 0.09 
GLP-1 analogues 278 (16) 241 (16) 37 (17) 0.71 
SGLT-2 inhibitors 123 (7) 103 (7) 20 (9) 0.21 
DDP4 inhibitors 263 (15) 224 (15) 39 (18) 0.13 
Glitazones 73 (4) 64 (4) 9 (4) 0.67 
ACE inhibitors 623 (36) 471 (31) 152 (70) < 0.01 
ARB 536 (31) 491 (32) 45 (21) < 0.01 
Alpha-blockers 76 (4) 62 (4) 14 (6) 0.13 
Beta-blockers 467 (27) 387 (25) 80 (37) < 0.01 
Calcium channel blockers 392 (22) 335 (22) 57 (26) 0.19 
Loop diuretics 75 (4) 62 (4) 13 (6) 0.22 
Thiazides 486 (28) 394 (26) 92 (42) < 0.01 
Statins 1182 (68) 1032 (68) 150 (69) 0.80 
Fibrates 103 (6) 85 (6) 18 (8) 0.08 
Aspirin  567 (32) 466 (31) 101 (46) < 0.01 
Other anti-platelet agentsc 130 (8) 106 (7) 24 (11) 0.04 
 2 
N (%, rounded) GLP-1 denotes glucagon-like peptide-1, SGLT-2 sodium-glucose cotransporter-2, DDP-4 3 
dipeptidyl peptidase-4, ACE angiotensin-converting-enzyme and ARB angiotensin-II-receptor blockers. P 4 
value for chi-square test. aCKD273-classifier below or equal to the cut-off of 0.154. bCKD273-classifier 5 
above the cut-point of 0.154. cOther anti-platelet agents include Warfarin, Non-vitamin K-antagonistic oral 6 
anticoagulants (NOAC) and Clopidogrel. 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
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Figure 1 Receiver operating characteristics curve of known risk factors for diabetic nephropathy 1 
(gender, diabetes duration, systolic blood pressure, eGFR, UACR, HbA1c, smoking, retinopathy 2 
and use of RAS-blocking agents) predicting CKD273 risk strata. Gender, UACR, eGFR and use of 3 
RAS-blocking agents show significant predictive value (p < 0.01), AUC = 0.72 (95 % CI: 0.68 to 4 
0.75) for the model.  5 
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